Founders keep asking which early-feasibility destination is cheaper and faster: Latin America or Australia. They want a single winner. There is not one.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the comparison I reuse when a US MedTech team has already heard the Australia CTN story and the LATAM cost story, and needs a decision frame instead of a brochure. It sits next to the live Australia vs Latin America FIH note and the Early Feasibility Studies pillar.
One-sentence answer
Latin America is usually cheaper per patient and can be faster to first patient when the dossier, ethics stack, and import plan are built for the country you chose. Australia stays faster to start when you need an English academic workflow and you are not ready to run a Spanish or Portuguese trámite. Neither wins if the protocol cannot support the FDA conversation you need next.
Cheaper is not the same as lower total cost
Per-patient cost in Colombia or Panama is often in a planning band about 40–60% below a comparable US or Australian number for similar procedure work. That band is experience-based from bioaccess® programs since 2010 — not a quote for your protocol.
Total program cost only wins if you do not pay for a second early feasibility study because the first one was exploratory in a way FDA later ignores. A cheaper study that cannot travel into an IDE conversation under 21 CFR 812.28 is a redo, not a savings.
Faster depends on which clock you mean
Australia. CTN/CTX and English ethics make the path look short. The CTN is often not the critical path. Site contracting, device import, and hospital activation still stack. Sponsors who budget “12 weeks to first patient in” from a CTN slide routinely discover the bottleneck was logistics.
Latin America. There is no single LATAM clock. Colombia (INVIMA), Brazil (ANVISA), Mexico (COFEPRIS), Argentina (ANMAT), and Panama (MINSA / CNBI-accredited ethics) have different ethics and regulator stacks. Panama’s ethics-committee-driven pathway for many early device studies can land in a planning band of about 3–5 months from submission to first patient when the file is complete. Colombia’s CEI clock and INVIMA clock are not the same clock. Pick the country before you translate the packet.
Four filters that decide the winner
1. Language and dossier. Australia keeps an English core. LATAM usually does not. INVIMA’s traducción oficial is not a certified PDF from a US vendor. Plan translation from the source language on day one.
2. Ethics vs regulator. In both regions, ethics can move while another gate is still open. In Australia, HREC approval does not mean the site is open. In Colombia, ethics clearance is not INVIMA authorization. In Panama, Decreto Ejecutivo No. 21 of 2026 (Gaceta Oficial No. 30510-C) sets RESEGIS registration and Type II ethics accreditation as process gates — not as a reason to skip import planning.
3. Import and device custody. A first-in-human implant or catheter does not travel like a pill. Importer of record, customs, and cold chain decide whether first patient slips after every approval is “done.”
4. FDA usability. Foreign clinical data can support an IDE conversation when protocol, monitoring, and endpoints were written for that use under 21 CFR 812.28 and ISO 14155. Acceptance is still FDA’s call per submission.
When Australia is the better early-feasibility pick
Pick Australia when the device already fits an English academic workflow, the implanting volume you need exists there, and your next FDA interaction is weeks away rather than a full year of LATAM build. It is also the better default if you have no in-country regulatory infrastructure in Latin America and you are not willing to build it for this study.
When Latin America is the better early-feasibility pick
Pick Latin America when enrollment speed and procedure volume are the constraint — structural heart, neurovascular, and other high-volume hospital procedures — and you will treat INVIMA, ANVISA, COFEPRIS, or Panama’s CNBI-accredited pathway as a designed pathway instead of a translated Australian packet. It is also the better default when you already need a LATAM authorized representative or in-country holder for a later commercial filing. Trial import and later registro are different trámites; they reward the same discipline.
The mistake that burns both options
Copying a US protocol, swapping the letterhead, and calling it an OUS early feasibility study. Australia will make that look viable longer than it is. Latin America will often reject it earlier on a form or a translation, which feels slower and is usually cheaper than discovering after 20 patients that the protocol cannot support the IDE.
Write the protocol for the data you need FDA to accept. Then pick the country whose ethics, import, and site-activation calendar can deliver that protocol. The region is a tactic. The evidence plan is the strategy.
Talk with bioaccess® when you need the Australia-vs-LATAM call tied to a concrete early feasibility country plan and an FDA-anchored evidence drawer. Market-access work after the trial is a separate path on our market access page.
Leave a Reply